LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events
Item 8.01
The Company will make several presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America ("SMSNA"), to take place October 24-27th 2019 in Nashville, TN. The presentations are filed as Exhibit 99.1, Exhibit 99.2, Exhibit 99.3, Exhibit 99.4, Exhibit 99.4 and Exhibit 99.5.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits are filed with this report:
| Exhibit No. | Description |
| 99.1 | Oral T (TLANDO) Reduces Liver Fat in Men with Liver Fat Slides |
| 99.2 | Improved Patient Reported Sexual and Mental Domain Outcomes with Oral Testosterone (TLANDO) Relative to Topical Testosterone in Treated Hypogonadal Men Poster |
| 99.3 | Symptomatic Response to TLANDO in Patients that do not Achieve T Cavg > 300 ng/dL Poster |
| 99.4 | Paradigm Shifting Beneficial Effects of TLANDO (Oral Testosterone) on Liver Poster |
Lipocine Inc. Exhibit
EX-99.1 2 tm1920614d1_ex99-1.htm EXHIBIT 99.1 1 Confidential 1 SMSNA 2019 October 25,…
To view the full exhibit click here
About LIPOCINE INC. (NASDAQ:LPCN)
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
